Fortune writer John Simons opines that a rumoredÂ merger of Pfizer and Wyeth would be all wrong for both companies. In his view, a merger would amount to a marriageÂ of weaknesses. Pfizer needs blockbusters to overcome looming patent expirations and Wyeth has recently been failing to deliver.
"Would the idea behind the merger be that misery loves company?" says Standard & Poors pharma analyst Herman Saftlas. "Most mergers in this sector haven't panned out from an earnings growth perspective. But even worse, these two companies are in the same boat."
- read Simon's opinion piece
Wyeth buyout a good deal for Pfizer? Report
What's next for Pfizer? Report
Wyeth stumbles badly trying to develop new drugs. Report